Summary
Global Markets Direct’s, ‘Cholera - Pipeline Review, H2 2016’, provides an overview of the Cholera pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Cholera, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Cholera and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Cholera
- The report reviews pipeline therapeutics for Cholera by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Cholera therapeutics and enlists all their major and minor projects
- The report assesses Cholera therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Cholera
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Cholera
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Cholera pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
Beijing Minhai Biotechnology Co., Ltd
MSD Wellcome Trust Hilleman Laboratories, Pvt. Ltd.
'
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Cholera Overview 6
Therapeutics Development 7
Pipeline Products for Cholera - Overview 7
Pipeline Products for Cholera - Comparative Analysis 8
Cholera - Therapeutics under Development by Companies 9
Cholera - Therapeutics under Investigation by Universities/Institutes 10
Cholera - Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Early Stage Products 13
Cholera - Products under Development by Companies 14
Cholera - Products under Investigation by Universities/Institutes 15
Cholera - Companies Involved in Therapeutics Development 16
Beijing Minhai Biotechnology Co., Ltd 16
MSD Wellcome Trust Hilleman Laboratories, Pvt. Ltd. 17
Cholera - Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Target 19
Assessment by Mechanism of Action 21
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Drug Profiles 27
cholera (trivalent) vaccine - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
cholera [strain O1/El/Tor/Ogawa] vaccine - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
cholera vaccine - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
Cholvax - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
crofelemer DR - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
gram-negative bacterial infections vaccine - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
IMSUTMR-1501 - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
Peptide for Cholera and Guillain-Barre Syndrome - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
Small Molecules for Bacterial Infections - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
Small Molecules to Inhibit Sialic Acid Permease for Gram Negative Bacterial Infections - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
Synthetic Peptides to Disrupt Cell Membrane for Bacterial and Fungal Infections - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
Cholera - Dormant Projects 40
Cholera - Discontinued Products 41
Cholera - Product Development Milestones 42
Featured News & Press Releases 42
Apr 27, 2016: Hilleman Laboratories Provides Phase I/II Update on Cholera Vaccine 42
Feb 03, 2015: Napo Files Brief on Appeal In Dispute With Salix 42
Appendix 44
Methodology 44
Coverage 44
Secondary Research 44
Primary Research 44
Expert Panel Validation 44
Contact Us 44
Disclaimer 45
List of Tables
Number of Products under Development for Cholera, H2 2016 7
Number of Products under Development for Cholera - Comparative Analysis, H2 2016 8
Number of Products under Development by Companies, H2 2016 9
Number of Products under Investigation by Universities/Institutes, H2 2016 10
Comparative Analysis by Late Stage Development, H2 2016 11
Comparative Analysis by Clinical Stage Development, H2 2016 12
Comparative Analysis by Early Stage Development, H2 2016 13
Products under Development by Companies, H2 2016 14
Products under Investigation by Universities/Institutes, H2 2016 15
Cholera - Pipeline by Beijing Minhai Biotechnology Co., Ltd, H2 2016 16
Cholera - Pipeline by MSD Wellcome Trust Hilleman Laboratories, Pvt. Ltd., H2 2016 17
Assessment by Monotherapy Products, H2 2016 18
Number of Products by Stage and Target, H2 2016 20
Number of Products by Stage and Mechanism of Action, H2 2016 22
Number of Products by Stage and Route of Administration, H2 2016 24
Number of Products by Stage and Molecule Type, H2 2016 26
Cholera - Dormant Projects, H2 2016 40
Cholera - Discontinued Products, H2 2016 41
List of Figures
Number of Products under Development for Cholera, H2 2016 7
Number of Products under Development for Cholera - Comparative Analysis, H2 2016 8
Number of Products under Development by Companies, H2 2016 9
Number of Products under Investigation by Universities/Institutes, H2 2016 10
Comparative Analysis by Clinical Stage Development, H2 2016 12
Comparative Analysis by Early Stage Products, H2 2016 13
Assessment by Monotherapy Products, H2 2016 18
Number of Products by Targets, H2 2016 19
Number of Products by Stage and Targets, H2 2016 19
Number of Products by Mechanism of Actions, H2 2016 21
Number of Products by Stage and Mechanism of Actions, H2 2016 21
Number of Products by Routes of Administration, H2 2016 23
Number of Products by Stage and Routes of Administration, H2 2016 23
Number of Products by Molecule Types, H2 2016 25
Number of Products by Stage and Molecule Types, H2 2016 25
